ARTICLE | Emerging Company Profile

Subcutaneous solution

Arsia is reducing biologics viscosity to enable subcutaneous delivery

December 14, 2015 8:00 AM UTC

Subcutaneous delivery of biologics can eliminate or reduce visits to a hospital or doctor's office, but at the high concentrations required, an increase in interactions between the molecules causes most biologics to become too viscous and painful to administer subcutaneously. Arsia Therapeutics Inc. is developing a library of excipients that disrupt the interactions between the protein molecules without interfering with the proteins themselves.

The company's technology consists of the excipients themselves, plus an algorithm that matches a particular biologic to an initial slate of excipients predicted to be optimally compatible based on undisclosed characteristics of the excipients and the therapeutics. ...